



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

March 24, 2021

Stephen Hurly  
Chief Executive Officer  
LAVA Therapeutics BV  
Yalelaan 60  
3584 CM Utrecht, the Netherlands

**Re: LAVA Therapeutics BV  
Form F-1  
Exhibit Nos. 10.1 and 10.2  
Filed March 2, 2021  
File No. 333-253795**

Dear Mr. Hurly:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance

cc: Joshua A. Kaufman, Esq